US20030104076A1 - Process for preparing dry extracts - Google Patents

Process for preparing dry extracts Download PDF

Info

Publication number
US20030104076A1
US20030104076A1 US10/290,121 US29012102A US2003104076A1 US 20030104076 A1 US20030104076 A1 US 20030104076A1 US 29012102 A US29012102 A US 29012102A US 2003104076 A1 US2003104076 A1 US 2003104076A1
Authority
US
United States
Prior art keywords
fluid
solid phase
microcrystalline cellulose
dry
silicified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/290,121
Inventor
Wilhelm Berkulin
Karl-Hans Theissing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J Rettenmaier and Soehne GmbH and Co KG
Original Assignee
Penwest Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceuticals Co filed Critical Penwest Pharmaceuticals Co
Priority to US10/290,121 priority Critical patent/US20030104076A1/en
Assigned to FINZELBERG GMBH & CO., KG reassignment FINZELBERG GMBH & CO., KG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BERKULIN, WILHELM, THEISSING, KARL-HANS
Publication of US20030104076A1 publication Critical patent/US20030104076A1/en
Assigned to PENWEST PHARMACEUTICALS CO. reassignment PENWEST PHARMACEUTICALS CO. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FINZELBERG GMBH & CO. KG
Assigned to J. RETTENMAIER & SOEHNE GMBH + CO. KG reassignment J. RETTENMAIER & SOEHNE GMBH + CO. KG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PENWEST PHARMACEUTICALS CO.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/77Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962Allium, e.g. garden onion, leek, garlic or chives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/04Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Definitions

  • the present invention relates to new processes for preparing dry extracts having superior flow characteristics, and extracts made by such processes.
  • Biologically, chemically and/or pharmaceutically active agents are often derived from natural sources in liquid form (including solutions, suspensions, emulsions, slurrys, pastes or other mixtures, hereinafter, “fluid”). This is particularly the case with plant extracts. Extracts from plant parts and/or plant preparations are widely employed in many industries, including but not limited to the feed, food, functional food, nutraceutical, dietary supplement and pharmaceutical industries. It is often desirable to dry these extracts to reduce their volume and/or to improve their handling and processing characteristics.
  • Spray drying is a known and very important method for dehydrating or drying fluids, fluid foods and botanical extracts.
  • spray drying involves the formation of small droplets of an extract or other fluid to be dried (hereafter, “extract”) followed by contacting the droplets with a heated gas to remove moisture.
  • extract an extract or other fluid to be dried
  • Conventional spray drying typically includes: creation and possibly concentration of a fluid extract; atomization of the extract into droplets; drying the droplets in stream of hot, dry gas such as heated air; separation of the resulting dry powder product from the moistened air; and finally cooling and packaging the product.
  • auxiliary agents such as excipients are often used in the processing of the extract to impart to the extract improved properties, for instance improved tabletting, handling, storage or processing properties.
  • auxiliary agents are typically in solid (dry powder) form and are conventionally admixed with the fluid extract. Droplets of the fluid mixture containing the extract and the auxiliary agent are commonly dried in a spray drying process as outlined above. Depending on what use is intended for the thus obtained dry products, further processing steps, such as wet granulation, fluidized-bed drying, compaction, etc., may follow.
  • Auxiliary agents are also commonly mixed in powder form with previously spray dried extract. This mixing of powders is also problematic because these blends still show dust formation, elevated moisture uptake and hygroscopicity, particle separation due to different particle density and size, and inferior compaction and compression properties and thus, also results in mixtures having inferior handling and tabletting properties.
  • the process of the present invention employs the novel and additional feature of dry powder injection. Rather than admixing the powdered auxiliary agent into the fluid extract and thus wetting the auxiliary agent, dry auxiliary agent is injected into a spray dryer contemporaneously with the injection and atomization of the fluid extract.
  • the process according to the invention results in adhesion of the auxiliary agents to the extract, thereby forming agglomerated particles. More specifically, wet extract droplets formed by the spraying mix and agglomerate and/or aggregate with at least one additional substance and are dried on their common way through the spray-dryer.
  • the residual moisture of the product of the inventive process is generally below 5%.
  • the so formed agglomerated particles possess remarkable and advantageous properties. Due to the outstanding properties of the obtained products, like superior flow characteristics compared to prior art compositions, the new agglomerates allow faster processing for manufacturing final dosage forms including tablet, capsules, granulates and powder blends. Surprisingly, even extract products which are usually hygroscopic when processed with additional substances according to conventional methods can be obtained as free flowing powder when the inventive process disclosed here is employed.
  • a homogeneous free-flowing powder can be obtained which can be used, for example, directly for tableting and/or compaction.
  • Such a product is superior to both one obtained by commonly drying a solution of the extract and auxiliary agent, and one obtained by adding the auxiliary agent to the dried extract, with respect to galenic properties, especially tableting property.
  • the proportion of auxiliary agent can be significantly reduced as compared to conventional processes, so that smaller tablets can be produced with the same load of active substance, or more active substance can be introduced in predetermined tablet sizes.
  • the invention also relates to dry extracts obtained by the inventive “dry” process, and to medications containing such extracts.
  • FIG. 1 depicts schematically the spray drying process which is the subject of the present invention.
  • FIG. 2 is a scanning electron micrograph of an agglomerated particle comprising extract of Ginseng and silicified/silicated microcrystalline cellulose, magnified at 3,000 ⁇ .
  • FIG. 3 is a scanning electron micrograph of an agglomerated particle comprising extract of Glucosamine and silicified/silicated microcrystalline cellulose, magnified at 3,000 ⁇ .
  • FIG. 4 is a scanning electron micrograph of an agglomerated particle comprising extract of St. John's Wort and silicified/silicated microcrystalline cellulose, magnified at 10,000 ⁇ .
  • FIG. 5 is a scanning electron micrograph of an agglomerated particle comprising extract of St. John's Wort and silicified/silicated microcrystalline cellulose, magnified at 10,000 ⁇ .
  • FIG. 1 A schematic depiction of a spray drying system employed in practicing the method of the invention is shown in FIG. 1.
  • a spray drying system employed in practicing the method of the invention is shown in FIG. 1.
  • Such a system includes a dry powder injector necessary to obtain the powder products having extraordinary characteristics.
  • the inventive spray drying process includes essentially a three-phase drying process involving both particle formation and drying.
  • a fluid extract is flowed through fluid feed 3 and is atomized, via an atomizer 4 into a spray of fine droplets within a drying chamber 6 .
  • a solid (dry powder) component is injected into the drying chamber from a dry powder feed 1 via a pneumatic feeding system 2 .
  • the result is a mixture 13 within the chamber of fine fluid droplets in close and intimate contact with powder particles.
  • a heated gas stream 5 suspends the droplets and powder particles, evaporating the fluid and leaving the solids in essentially their original size and shape. Many droplets in close contact with powder particles agglomerate or aggregate during the drying process, forming new powders with superior flow and other handling characteristics.
  • the dried powder is separated from the gas stream and collected.
  • Spent drying gas is either treated and exhausted to the atmosphere or re-circulated to the system. More specifically, the powder is separated from the drying gas at the bottom of the drying chamber. Most often, the gas exits through an outlet duct 11 in the center of the cone portion of the drying chamber. Heavier or coarser particles will be separated at this point, dropping into the cone to be collected through an air lock 8 and into apparatus 10 for further processing. Then, either cyclones 7 or fabric filters 12 (or both) remove the remaining powder from the exit gas and add that collected powder to the further processing apparatus through a second air lock 9 . In systems producing a very fine powder, most of the collection takes place at this point.
  • the present invention is not limited to the above spray dryer type, but rather includes other types of spray dryers such as a box spray dryer employing the Rogers process, spray-belt dryers, and more.
  • Precise drying conditions vary in accordance with the extract and auxiliary agents employed.
  • spray-drying plant can be used in which the fluid extract is introduced into a spray tower and drying air is simultaneously fed. By spraying into a hot-air current, the fluid products are quickly and mildly dried within seconds or fractions of seconds.
  • the fluid extract to be dried typically contains from 5 to 70% of dry substance and is introduced into a spray tower and atomized at a pressure within a range of from 10 to 150 bar through one or more high-pressure nozzles.
  • the temperature of the fed-in drying air is between 120 and 350° C.
  • the dry additional substance or a mixture of such substances is also introduced into the spray tower using blow conveyance, preferably in the vicinity of the spraying nozzles for the fluid extract.
  • Centrifugal atomization the most common, uses a rotating wheel or disc to break the fluid stream into droplets. The rotational speed determines the mean particle size.
  • Hydraulic pressure-nozzle atomization forces pressurized fluid through an orifice. Multiple nozzles are used to increase capacity. The particle size depends on the pressure drop across the orifice, so that the orifice size determines the capacity of the system.
  • Two-fluid pneumatic atomization uses nozzles, as well, but introduces a second fluid, usually compressed air (often called high pressure spray jets), into the fluid stream to atomize it.
  • a second fluid usually compressed air (often called high pressure spray jets)
  • a disperser brings the heated gas into contact with the droplets.
  • the disperser must accomplish three things: mix the gas with the droplets, begin the drying process, and determine the flow paths through the drying chamber.
  • the drying gas may be heated directly by combustion of natural gas, propane, or fuel oil, or indirectly using shell-and-tube or finned heat exchangers.
  • an addition equipment necessary to feed dry auxiliary agent in the top part close to the atomizer and hot air entrance is essential for the process of producing the free flowing and direct compressible product powder.
  • the drying chamber must be sized to allow adequate contact time for evaporation of all of the fluid to produce a dry powder product. Factors that impact the drying time include the temperature difference between the droplets and the drying gas, and their flow rates.
  • the exact shape of the chamber depends on the drying characteristics and product specifications, but most are cylindrical with a cone-shaped lower section to facilitate collection of the product.
  • the invention is not limited to botanical or plant extracts but applicable for all types of food, functional food, dietary supplements, nutraceuticals as well as drugs, pharmaceuticals, and other (bio)active agents for human and animal use.
  • the later which may be used in. accordance with the embodiments described above include therapeutic agents, either systemically or locally applied, biocides, bactericides, pesticides, herbicides, fungicides, fertilizers, repellents, disinfectants, detergents, aromas, fragrances, and others.
  • the therapeutics may include analgesics, anticonvulsants, antidiabetic agents, antidotes, antifibrosis agent, antihistamines, anti-infective agents, like amebicides, anthelmintics, and different classes of antibiotics, antifungals, antiviral substances, antineoplastics, antirheumatic and cardiovascular agents, central nervous actives, deodorants, erectile dysfunction enhancer, gastrointestinal agents, homeopathic remedies, hormones, immunoregulators, ophthalmic and osteoporosis agents, psychotherapeutics, respiratory agents, sedatives and hypnotics, skin and mucous membrane agents, urinary tract agents, vaginal preparations, and vasodilators.
  • analgesics include analgesics, anticonvulsants, antidiabetic agents, antidotes, antifibrosis agent, antihistamines, anti-infective agents, like amebicides, anthelmintics, and different classes of antibiotics,
  • Botanical preparations include but are not limited to partial or complete extracts from medical, spice and/or food plants or parts thereof, especially: Abelmoschus moschatus, Acanthopanax sessiliflorum, Achyrocline satureoides, Acorns calamus, Aesculus hippocastanum, Albizzia julibrissin, Alchornea castaneifolia, Aleo vera, Aleo arborescnes, Allium-species (e.g., A. cepa, A. ursinum, A.
  • sorbilis Petroselinum crispum, Peumus boldus, Pfaffia paniculata, Phaseolus vulgaris, Phyllanthus niruri, Physalis angulata, Pilocarpus jaborandi, Pimenta dioica, Pimpinella anisum, Piper angustifolium, Piper methysticum, Pogostemon patchouli, Polypodium lepidopteris, Prunus laurocerasus, Psidium guajava, Ptychopetalum olacoides, Rhodiola crenulata, Rhodiola rosea, Rhus aromatics, Rosmnarinus officinalis, Rubia tinctorum, Rubus fructicosus, Ruscus aculeatus, Ruta graveolens, Sabal serulata, Salix alba, Salvia, Sambucus nigra and S.
  • the presented invention is extraordinary valuable, if the active agent is hygroscopic, for instance, hygroscopic herbal extracts including but not limited to St. John's Wort, Artichoke, Valerian, and Ginseng.
  • Dietary supplements or nutraceuticals include but are not limited to the groups of amino acids, vitamins, minerals, and trace elements, as well as ergogens and metabolites.
  • These active agent including in particular the non-proteinogenic amino acids Creatine, Taurine, or branch-chained amino acids, Leucine, Isoleucine, Valine, or neurotransmitter precursors tyrosine, phenylalanine, tryptophane, or Arginine, Ornithine, Citrulline, Glutamine, in their water-free form, the hydrated or in form of its salt, or derivatives or metabolites thereof
  • the purins include especially are caffeine, theobromine, or theophylline, as sole substances or in form of their plant origin or extracts thereof
  • the vitamins include especially Vitamin A, B-complex, C, D, E, K, ⁇ -carotin, Nicotinamide, Folic acid, Coenzym Q10, NADH, L-Carnitine, alpha-lipoic
  • the process is particularly useful if the fluid extract is the extract of a medicinal plant whose extract is to be administered in the form of tablets.
  • Said at least one additional substance will then be a galenic auxiliary agent.
  • Galenic auxiliary agents are known to the skilled person. There may be mentioned, for example, lactose, maltodextrin, dextrin, dry glucose, starch, microcrystalline cellulose, chemically and physically modified microcrystalline cellulose including silicated/silicified microcrystalline cellulose or derivatives thereof (e.g., the trademarked product from Penwest Pharmaceuticals, Inc.
  • Prosolv SMCC 50, 90, Prosolv HD, and other grades physical blends of microcrystalline cellulose and silicon dioxide, Povidone®, polyethylene glycol, calcium phosphate, magnesium stearate, precipitated silicic acid, precipitated silica, highly dispersed silica, sorbitol, mannitol, or mixtures thereof.
  • Silicified/silicated microcrystalline cellulose is a particulate agglomerate of coprocessed microcrystalline cellulose and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other.
  • the silicon dioxide has a particle size from about 1 nanometer to about 100 microns, based on average primary particle size.
  • the silicon dioxide is a grade of colloidal silicon dioxide.
  • Silicified/silicated microcrystalline cellulose is sold commercially by Penwest Pharmaceuticals, Inc. under the trademark “ProSolv”, and is described in U.S. Pat. No. 5,585,115. This application incorporates by reference the definitions of those terms as defined by the Dictionary.com internet web site, which is consistent with art recognized meanings of these terms. Specifically, “silicated” is defined as “combined or impregnated with silicon or silica”; and “silicified” is defined as “convert[ed] into or impregnate[d] with silica”. Silicified microcrystalline cellulose, also called silicated microcrystalline cellulose, is a preferred auxiliary galenic agent.
  • the obtained free flowable powders comprise agglomerated particles may combined with conventional tableting additives prior to tableting, capsules filling, or further blending.
  • Those additives may be soluble or insoluble inert pharmaceutical diluents, lubricants, agents for enteric, hydrophilic and hydrophobic coating, substances to achieve sustained and controlled release profile of the actives.
  • the additives are suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, gelatin, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose and the like.
  • additives include, e.g., antioxidants and preservatives, coloring, flavoring and diluting agents, emulsifying and suspending agents, such as acacia, agar, alginic acid, sodium alginate, bentonite, carbomer, carrageenan, carboxymethylcellulose, cellulose, cholesterol, gelatin, hydroxyethyl cellulose, hydroxppropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, oleyl alcohol, povidone, propylene glycol monostearate, sodium lauryl sulfate, sorbitan esters, stearyl alcohol, tragacanth, xanthan gum, and derivatives thereof, solvents, and miscellaneous ingredients such as microcrystalline cellulose, citric acid, dextrin, dextrose, fluid glucose, lactic acid, lactose, magnesium chloride, potassium metaphosphate, starch, and the like. Those components may either be co-sprayed or blended together with the product obtained according
  • the particle size of the additional substance employed is of less importance. Suitable particle sizes are within a range of 1 to 800 ⁇ m, preferably within the range of 1 to 500 ⁇ m, more preferably in the range of 100 to 300 ⁇ m.
  • the orally applicable product form which comprises about 45-95%, preferably from 60 to 80%, active agent, in particular, a botanical extract and about 5 to 55%, preferably from 40 to 20%, of a galenic auxiliary agent added as dry powder during the spray drying process.
  • the structure of the spray dried powder particles is crucial for its physical characteristics.
  • the physical properties of spray dried powders is related to the characteristics of the matrix of the shells (outer layer) and the size of the inner core.
  • FIGS. 2 - 5 scanning electron microscopy
  • a fluid extract is provided in a storage vessel. Also provided separately are dosing scales with the additional substance employed according to the invention in a dry form.
  • the fluid extract or an aqueous solution of the active agent is sprayed into a drying chamber with the finely powdered additional substance at the top of the spray tower through high-pressure nozzles using a pump.
  • Hot air is introduced into the spray tower from below (or top).
  • the exhaust air leaves at the top end (or center) of the spray tower and is optionally conducted to a heat exchanger.
  • the dried product is conducted onto a vibrating bed at the lower end of the spray tower and introduced into the further production process. Alternatively, the product may be fed into a cyclone.
  • Example 1 5.0 kgs of commonly produced St. John's wort dry extract comprising of 65% native extract and about 35% excipients like Maltodextrin (30%) and silicon dioxide (5%) was added to 2,5 kgs of silicified/silicated microcrystalline cellulose and mixed in a pilot plant blender.
  • the moisture uptake, the powder flowability and the compactability was compared with product of Example 1 in Table 1: TABLE 1 Comparison of Properties of St. John's Wort Products Hardness of Hardness of Moisture Compact- the pressed the pressed Speed of Product Flowability Uptake ability tablets tablets Encapsulation St. John's Wort Very good Low Very good High High - No High - No of Example 1 stop stops necessary necessary St. John's Wort Good Fair Poor Fair Poor - Poor - Multiple of Comp. Multiple stop stops for Example 1 for cleaning cleaning
  • Example 1 similar products of the following botanical extracts and nutraceuticals or dietary supplements (DS) were manufactured. 15 to 245 kg fluid feed of below shown botanical extracts or dietary supplement solutions having a dry content of 32 to 53% were spray-dried together with 25 to 40% of dry silicified/silicated microcrystalline cellulose at an air entry temperature of 175-250° C. and under a nozzle pressure of about 40 bar to obtain dry product with yields of 85 to 95%.
  • valerian root extract having a dry content of 51.8% was spray-dried together with 332.00 kg of dry glucose and 48.6 kg of highly dispersed silica at an air entry temperature of 230° C. and under a nozzle pressure of 80 bar to obtain 1142.8 kg of dry free-flowing extract powder.
  • Example 1 similar products comprising the dietary supplements Glucosamine and Chrondroitin with specialty auxiliary blend were manufactured. 47.6 kgs of Glucosamine sulfate and 38.1 kgs of Chrondroitin were dissolved in water to obtain the fluid feed. As dry powder feed a blend of dry silicified/silicated microcrystalline cellulose (11.9 kgs) and colloidal silicon dioxide (Aerosil 200; 2.4 kgs) were mixed. At an air entry temperature of 220° C. and under a nozzle pressure of about 40 bar the fluid and powder feed were co-spray-dried according to the example 1 to obtain dry product with yields of 93%.

Abstract

Processes for preparing dry extracts from fluid extracts and at least one additional substance by a spray-drying process is effected by adding the additional substance to the spray-drying process in a dry form.

Description

    RELATED APPLICATION
  • This application is a continuation-in-part of U.S. application Ser. No. 09/986,116 filed Nov. 7, 2001, which is incorporated herein by reference in its entirety.[0001]
  • The present invention relates to new processes for preparing dry extracts having superior flow characteristics, and extracts made by such processes. [0002]
  • BACKGROUND
  • Biologically, chemically and/or pharmaceutically active agents are often derived from natural sources in liquid form (including solutions, suspensions, emulsions, slurrys, pastes or other mixtures, hereinafter, “fluid”). This is particularly the case with plant extracts. Extracts from plant parts and/or plant preparations are widely employed in many industries, including but not limited to the feed, food, functional food, nutraceutical, dietary supplement and pharmaceutical industries. It is often desirable to dry these extracts to reduce their volume and/or to improve their handling and processing characteristics. [0003]
  • Spray drying is a known and very important method for dehydrating or drying fluids, fluid foods and botanical extracts. In its conventional form, spray drying involves the formation of small droplets of an extract or other fluid to be dried (hereafter, “extract”) followed by contacting the droplets with a heated gas to remove moisture. Conventional spray drying typically includes: creation and possibly concentration of a fluid extract; atomization of the extract into droplets; drying the droplets in stream of hot, dry gas such as heated air; separation of the resulting dry powder product from the moistened air; and finally cooling and packaging the product. [0004]
  • Auxiliary agents such as excipients are often used in the processing of the extract to impart to the extract improved properties, for instance improved tabletting, handling, storage or processing properties. Such auxiliary agents are typically in solid (dry powder) form and are conventionally admixed with the fluid extract. Droplets of the fluid mixture containing the extract and the auxiliary agent are commonly dried in a spray drying process as outlined above. Depending on what use is intended for the thus obtained dry products, further processing steps, such as wet granulation, fluidized-bed drying, compaction, etc., may follow. [0005]
  • In practice, this form of common spray drying results in products having undesirable characteristics, tending to form hygroscopic (moisture retaining) and therefore “sticky” or “gummy” products. These sticky materials often deposit and build up in layers during the drying process, resulting in product which is unable to trickle as fine particle and flow as powder through subsequent product conveying and packaging steps, for instance product transport through pipes and tubes. Attempts to apply a common spray dry process therefore often fail. [0006]
  • Auxiliary agents are also commonly mixed in powder form with previously spray dried extract. This mixing of powders is also problematic because these blends still show dust formation, elevated moisture uptake and hygroscopicity, particle separation due to different particle density and size, and inferior compaction and compression properties and thus, also results in mixtures having inferior handling and tabletting properties. [0007]
  • OBJECTS OF THE INVENTION
  • In view of the shortcomings of conventional extract spray drying processes, it is an object of the present invention to overcome the above-described problems and to provide a process for manufacturing free flowing product powders by spray drying. [0008]
  • It is a further object of the present invention to provide finished products that contain low amounts of auxiliary agents introduced during the drying process or thereafter. Such products would enable further confectionery steps, for instance direct compression to produce tablets or direct compaction to produce granules, without adding large or any amounts of additional excipients. [0009]
  • Additionally, it is an object of the present invention to provide a particularly simple process for adding further substances in dry form to an extract to be dried, with the goal to obtain material which is more easily handled and processed. [0010]
  • Finally, it is an object of the invention to provide a process for preparing dry extracts from fluid extracts and at least one additional substance by a spray-drying process, wherein the additional substance is added to the spray-drying process in a dry form during the spray-drying process. [0011]
  • These and other objects of the invention will become more clear in view of the disclosure of the inventive spray dry technology which follows. [0012]
  • SUMMARY OF THE INVENTION
  • The above objects are achieved by a process for preparing dry extracts from a fluid extract and at least one additional substance by a spray drying process, wherein said at least one additional substance is added to the spray drying process in a dry form during the spray drying process. [0013]
  • That is, the process of the present invention employs the novel and additional feature of dry powder injection. Rather than admixing the powdered auxiliary agent into the fluid extract and thus wetting the auxiliary agent, dry auxiliary agent is injected into a spray dryer contemporaneously with the injection and atomization of the fluid extract. [0014]
  • The process according to the invention results in adhesion of the auxiliary agents to the extract, thereby forming agglomerated particles. More specifically, wet extract droplets formed by the spraying mix and agglomerate and/or aggregate with at least one additional substance and are dried on their common way through the spray-dryer. The residual moisture of the product of the inventive process is generally below 5%. [0015]
  • The so formed agglomerated particles possess remarkable and advantageous properties. Due to the outstanding properties of the obtained products, like superior flow characteristics compared to prior art compositions, the new agglomerates allow faster processing for manufacturing final dosage forms including tablet, capsules, granulates and powder blends. Surprisingly, even extract products which are usually hygroscopic when processed with additional substances according to conventional methods can be obtained as free flowing powder when the inventive process disclosed here is employed. [0016]
  • Also surprisingly, in this way a homogeneous free-flowing powder can be obtained which can be used, for example, directly for tableting and/or compaction. Such a product is superior to both one obtained by commonly drying a solution of the extract and auxiliary agent, and one obtained by adding the auxiliary agent to the dried extract, with respect to galenic properties, especially tableting property. Thus, the proportion of auxiliary agent can be significantly reduced as compared to conventional processes, so that smaller tablets can be produced with the same load of active substance, or more active substance can be introduced in predetermined tablet sizes. Remarkable are the properties of less hygroscopicity, or at least the better flow characteristic with the same moisture uptake, and the improved compressibility with less quantity of added auxiliary agents compared with the conventional obtained botanical extract composition of prior art. The advantages of the present invention are clearly demonstrated within the below detailed description, examples and the presented tables showing comparable data. [0017]
  • The invention also relates to dry extracts obtained by the inventive “dry” process, and to medications containing such extracts. [0018]
  • The foregoing has outlined rather broadly the features and technical advantages of the present invention in order that the detailed description of the invention that follows may be better understood. Additional features and advantages of the invention will be described hereinafter which form the subject of the claims of the invention. It should be appreciated by those skilled in the art that the conception and specific embodiment disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present invention. It should also be realized by those skilled in the art that such equivalent constructions do not depart from the spirit and scope of the invention as set forth in the appended claims. The novel features which are believed to be characteristic of the invention, both as to its organization and method of operation, together with further objects and advantages will be better understood from the following description when considered in connection with the accompanying figures. It is to be expressly understood, however, that each of the figures is provided for the purpose of illustration and description only and is not intended as a definition of the limits of the present invention.[0019]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • For a more complete understanding of the present invention, reference is now made to the following descriptions taken in conjunction with the accompanying drawings, in which: [0020]
  • FIG. 1 depicts schematically the spray drying process which is the subject of the present invention. [0021]
  • FIG. 2 is a scanning electron micrograph of an agglomerated particle comprising extract of Ginseng and silicified/silicated microcrystalline cellulose, magnified at 3,000×. [0022]
  • FIG. 3 is a scanning electron micrograph of an agglomerated particle comprising extract of Glucosamine and silicified/silicated microcrystalline cellulose, magnified at 3,000×. [0023]
  • FIG. 4 is a scanning electron micrograph of an agglomerated particle comprising extract of St. John's Wort and silicified/silicated microcrystalline cellulose, magnified at 10,000×. [0024]
  • FIG. 5 is a scanning electron micrograph of an agglomerated particle comprising extract of St. John's Wort and silicified/silicated microcrystalline cellulose, magnified at 10,000×.[0025]
  • DETAILED DESCRIPTION OF THE INVENTION
  • A schematic depiction of a spray drying system employed in practicing the method of the invention is shown in FIG. 1. Such a system includes a dry powder injector necessary to obtain the powder products having extraordinary characteristics. [0026]
  • In particular, and referring to FIG. 1, the inventive spray drying process includes essentially a three-phase drying process involving both particle formation and drying. In a first phase, a fluid extract is flowed through fluid feed [0027] 3 and is atomized, via an atomizer 4 into a spray of fine droplets within a drying chamber 6. Contemporaneously, a solid (dry powder) component is injected into the drying chamber from a dry powder feed 1 via a pneumatic feeding system 2. The result is a mixture 13 within the chamber of fine fluid droplets in close and intimate contact with powder particles. A heated gas stream 5 suspends the droplets and powder particles, evaporating the fluid and leaving the solids in essentially their original size and shape. Many droplets in close contact with powder particles agglomerate or aggregate during the drying process, forming new powders with superior flow and other handling characteristics.
  • The dried powder is separated from the gas stream and collected. Spent drying gas is either treated and exhausted to the atmosphere or re-circulated to the system. More specifically, the powder is separated from the drying gas at the bottom of the drying chamber. Most often, the gas exits through an [0028] outlet duct 11 in the center of the cone portion of the drying chamber. Heavier or coarser particles will be separated at this point, dropping into the cone to be collected through an air lock 8 and into apparatus 10 for further processing. Then, either cyclones 7 or fabric filters 12 (or both) remove the remaining powder from the exit gas and add that collected powder to the further processing apparatus through a second air lock 9. In systems producing a very fine powder, most of the collection takes place at this point.
  • The present invention is not limited to the above spray dryer type, but rather includes other types of spray dryers such as a box spray dryer employing the Rogers process, spray-belt dryers, and more. [0029]
  • Drying Conditions
  • Precise drying conditions vary in accordance with the extract and auxiliary agents employed. For performing the process, as usual spray-drying plant can be used in which the fluid extract is introduced into a spray tower and drying air is simultaneously fed. By spraying into a hot-air current, the fluid products are quickly and mildly dried within seconds or fractions of seconds. The fluid extract to be dried typically contains from 5 to 70% of dry substance and is introduced into a spray tower and atomized at a pressure within a range of from 10 to 150 bar through one or more high-pressure nozzles. Usually, the temperature of the fed-in drying air is between 120 and 350° C. In the process according to the invention, the dry additional substance or a mixture of such substances is also introduced into the spray tower using blow conveyance, preferably in the vicinity of the spraying nozzles for the fluid extract. [0030]
  • Equipment
  • The selection and operation of the atomizer is of extreme importance in achieving an optimum operation and production of top-quality powders. Within large capacity spray dryer there can be found at least three main types of atomization: [0031]
  • Centrifugal atomization, the most common, uses a rotating wheel or disc to break the fluid stream into droplets. The rotational speed determines the mean particle size. [0032]
  • Hydraulic pressure-nozzle atomization forces pressurized fluid through an orifice. Multiple nozzles are used to increase capacity. The particle size depends on the pressure drop across the orifice, so that the orifice size determines the capacity of the system. [0033]
  • Two-fluid pneumatic atomization uses nozzles, as well, but introduces a second fluid, usually compressed air (often called high pressure spray jets), into the fluid stream to atomize it. [0034]
  • After atomization, a disperser brings the heated gas into contact with the droplets. The disperser must accomplish three things: mix the gas with the droplets, begin the drying process, and determine the flow paths through the drying chamber. The drying gas may be heated directly by combustion of natural gas, propane, or fuel oil, or indirectly using shell-and-tube or finned heat exchangers. [0035]
  • In accordance with one embodiment of the present invention, an addition equipment necessary to feed dry auxiliary agent in the top part close to the atomizer and hot air entrance is essential for the process of producing the free flowing and direct compressible product powder. [0036]
  • The drying chamber must be sized to allow adequate contact time for evaporation of all of the fluid to produce a dry powder product. Factors that impact the drying time include the temperature difference between the droplets and the drying gas, and their flow rates. The exact shape of the chamber depends on the drying characteristics and product specifications, but most are cylindrical with a cone-shaped lower section to facilitate collection of the product. [0037]
  • Finally, proper configuration of the atomizer, disperser, and drying chamber is essential for complete drying and to avoid the deposit of wet material on the interior surfaces of the dryer. Designs may use co-current, counter-current, or mixed flow patterns. [0038]
  • Active Agents
  • The invention is not limited to botanical or plant extracts but applicable for all types of food, functional food, dietary supplements, nutraceuticals as well as drugs, pharmaceuticals, and other (bio)active agents for human and animal use. The later, which may be used in. accordance with the embodiments described above include therapeutic agents, either systemically or locally applied, biocides, bactericides, pesticides, herbicides, fungicides, fertilizers, repellents, disinfectants, detergents, aromas, fragrances, and others. [0039]
  • The therapeutics may include analgesics, anticonvulsants, antidiabetic agents, antidotes, antifibrosis agent, antihistamines, anti-infective agents, like amebicides, anthelmintics, and different classes of antibiotics, antifungals, antiviral substances, antineoplastics, antirheumatic and cardiovascular agents, central nervous actives, deodorants, erectile dysfunction enhancer, gastrointestinal agents, homeopathic remedies, hormones, immunoregulators, ophthalmic and osteoporosis agents, psychotherapeutics, respiratory agents, sedatives and hypnotics, skin and mucous membrane agents, urinary tract agents, vaginal preparations, and vasodilators. [0040]
  • Botanical preparations include but are not limited to partial or complete extracts from medical, spice and/or food plants or parts thereof, especially: [0041] Abelmoschus moschatus, Acanthopanax sessiliflorum, Achyrocline satureoides, Acorns calamus, Aesculus hippocastanum, Albizzia julibrissin, Alchornea castaneifolia, Aleo vera, Aleo arborescnes, Allium-species (e.g., A. cepa, A. ursinum, A. sativum), Alpinia officinarum, Anethum graveolens, Anacardium occidentale, Ananas comosus, Andrographis paniculata, Angelica archangelica, Angelica dahurica, Angelica formosana, Annona muricata, Anthemis nobilis, Apium graveolens, Aralia species, Arctium major, Arctostaphylos uvaursi, Arnica montana, Artemisia absinthium, Artemisia dracunculus, Asparagus offic., Astragalus membranoceus, Atropa belladonna, Baccharis genistelloides, Bauhinia forficata, Berberis vulgaris, Bertholletia excelsa, Betula-species, Bidens pilosa, Bixa orellana, Boerhaavia diffusa, Boswellia serrata, Brassica nigra, Brunfelsia uniflorus, Bryonia dioica, Calycophyllum spruceanum, Camellia sinensis, Capsicum frutescens, Carapa guianensis, Carum carvi, Cassia occidentalis, Cayaponia tayuya, Centella asiatica, Cetraria islandica, Chamomilla romana, Chrysanthemum vulgare, Cicer arietum, Cimicifuga racemosa, Cinnamomum-species, Cissampelos pareira, Citrus-species, Codonoposis pilosula, Coffea arabica, Cola acuminata, Cola nitida, Commiphora mukul, Copaifera officinalis, Copaifera reticulate, Coptis chinensis, Cordyceps sinesis, Coriandrum sativum, Crataegus-species, Croton lechleri, Cucurbita pepo, Cuminum cyminum, Curcuma-species, Cusparia officinalis, Cynara scolymus, Desmodium adscendens, Dioscorea villosa, Dipterocarpus turbinatus, Drosera species, Echinacea angustifolia, Echinacea purpurea, Echinopanax elatus Nakai, Elettaria cardamonum, Eleutherococcus senticosus, Ephedra sinica, Equisetum arvense, Erythrina mulungu, Erythroxylum catuaba, Eucalyptus globules, Eucommia ulmoides, Fagopyrum vulgare, Foeniculum vulgare, Fumaria offic., Gandoerma lucidum, Gaultheria procumbens, Ginkgo biloba, Glycyrrhia glabra, Grifola frondosa, Guazuma ulmifolia, Hamamelis virginiana, Harpagopythum procumbens, Hedeoma pulegioides, Herniaria glabra, Hoppea dichotoma, Humulus lupulus, Hymenaea courbaril, Hypericum perforatum, Hysopus officinalis, Ilex paraguariensis, Illicium verum, Iluna helenium, Iris pallida, Jasminum grandiflorum, Juniperus communis, Larrea tridentate, Laurus nobilis, Lavendula officinalis, Lawsonia inermis, Lentinus edodes, Lepidium meyenii, Leuzea carthamoides, Levisticum officinale, Malpighia glabra, Matricaria chamomilla, Maytenus krukovit, Maytenus ilicifolia, Melaleuca, Melilotus officinalis, Melissa officinalis, Mentha piperita, Morinda citrifolia, Myrciara dubia, Myrcia salicifolia, Myristica fragrans, Myroxylon balsamum pereirae, Myrtus communis, Ocimum basilicum, Ocimum sanctum, Ocotea sassafras, Oenanthe aquatica, Olea europaea, Olibanum, Ononis spinosa, Origanum, Orthosiphon stamineus, Panax ginseng, Panax quinquefolium, Passiflora edulis, Passiflora incamata, Paullina cupana var. sorbilis, Petroselinum crispum, Peumus boldus, Pfaffia paniculata, Phaseolus vulgaris, Phyllanthus niruri, Physalis angulata, Pilocarpus jaborandi, Pimenta dioica, Pimpinella anisum, Piper angustifolium, Piper methysticum, Pogostemon patchouli, Polypodium lepidopteris, Prunus laurocerasus, Psidium guajava, Ptychopetalum olacoides, Rhodiola crenulata, Rhodiola rosea, Rhus aromatics, Rosmnarinus officinalis, Rubia tinctorum, Rubus fructicosus, Ruscus aculeatus, Ruta graveolens, Sabal serulata, Salix alba, Salvia, Sambucus nigra and S. ebulus, Santalum album, Sarothamnus scoparius, Sassafras albidum, Satureja hortensis, Schinus molle, Schisandra chinensis, Scopolia camiolica, Scopolia dulcis, Serenoa repens, Simarouba amara, Silybum marianum, Smilax officinalis, Smilax sarsaparilla, Solanum paniculatum, Solidago serotina, Solidago virgaurea, Stachytarpheta jamaicensis, Stevia rebaudiana, Symphytum officinale, Syzyqium aromaticum, Tabebuia avellanedae, Tabebuia impetiginosa, Tanacetum parthenium, Taraxacum officinale, Theobroma cacao, Thymus serpyllum, Thymus vulgaris, Tilia cordata, Tinospora cordifolia, Trichopus zeylanicus, Trifolium pratense, Trigonella foenum-graecum, Tumera aphrodisiaca, Tumera diffusa, Ulmus rubra, Uncaria tomentosa, Urtica dioica, Vaccinium macrocarpon, Vaccinium myrtillus, Valeriana officinalis, Vitex agnus-castus, Vitis vinifera, Withania somnifera, Zingiberis officinale, and other herbs, spices, or medicinal plants.
  • The presented invention is extraordinary valuable, if the active agent is hygroscopic, for instance, hygroscopic herbal extracts including but not limited to St. John's Wort, Artichoke, Valerian, and Ginseng. [0042]
  • Dietary supplements or nutraceuticals include but are not limited to the groups of amino acids, vitamins, minerals, and trace elements, as well as ergogens and metabolites. These active agent including in particular the non-proteinogenic amino acids Creatine, Taurine, or branch-chained amino acids, Leucine, Isoleucine, Valine, or neurotransmitter precursors tyrosine, phenylalanine, tryptophane, or Arginine, Ornithine, Citrulline, Glutamine, in their water-free form, the hydrated or in form of its salt, or derivatives or metabolites thereof, the purins include especially are caffeine, theobromine, or theophylline, as sole substances or in form of their plant origin or extracts thereof, the vitamins include especially Vitamin A, B-complex, C, D, E, K, β-carotin, Nicotinamide, Folic acid, Coenzym Q10, NADH, L-Carnitine, alpha-lipoic acid in free form, salt or ester form, the minerals and trace elements include especially Calcium, Magnesium, Sodium, Potassium, Chromium, Iodine, Manganese, Copper, Iron, Zinc, Vanadium, Phosphorus and Selenium, in physiologically acceptable form, as well as other groups of nutraceuticals, like Glucosamine, Chondroitin, Phytoestrogens, like Flavonoides (from Soy, Red clover) and Lignans (Flax seeds), Camosine, Ribose, Choline, Poly-unsaturated fatty acids, Antioxidants including but not limited to Anthocyans, Proanthocyanidines, Carotinoides (lutein, lycopene, astaxanthin, zeaxanthin), Phytin, Phytic acid, Policosanols, Policosanoic acids, Montanic acids, Phytosterols, Phytostanols, Pyruvates, Lecithin, Phosphatidylserine, Phosphatidylcholin, SAMe, 5-Hydroxytryptophan, Synephrine, prebiotic fibers, and the like. [0043]
  • Auxiliary Agents
  • The process is particularly useful if the fluid extract is the extract of a medicinal plant whose extract is to be administered in the form of tablets. Said at least one additional substance will then be a galenic auxiliary agent. Galenic auxiliary agents are known to the skilled person. There may be mentioned, for example, lactose, maltodextrin, dextrin, dry glucose, starch, microcrystalline cellulose, chemically and physically modified microcrystalline cellulose including silicated/silicified microcrystalline cellulose or derivatives thereof (e.g., the trademarked product from Penwest Pharmaceuticals, Inc. Prosolv SMCC 50, 90, Prosolv HD, and other grades), physical blends of microcrystalline cellulose and silicon dioxide, Povidone®, polyethylene glycol, calcium phosphate, magnesium stearate, precipitated silicic acid, precipitated silica, highly dispersed silica, sorbitol, mannitol, or mixtures thereof. [0044]
  • As used herein the terms “silicified” and “silicated” in the context of microcrystalline cellulose are used interchangeably to refer to a class of products which are particularly useful as a direct compression vehicle. Silicified/silicated microcrystalline cellulose is a particulate agglomerate of coprocessed microcrystalline cellulose and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide has a particle size from about 1 nanometer to about 100 microns, based on average primary particle size. Preferably, the silicon dioxide is a grade of colloidal silicon dioxide. [0045]
  • Silicified/silicated microcrystalline cellulose is sold commercially by Penwest Pharmaceuticals, Inc. under the trademark “ProSolv”, and is described in U.S. Pat. No. 5,585,115. This application incorporates by reference the definitions of those terms as defined by the Dictionary.com internet web site, which is consistent with art recognized meanings of these terms. Specifically, “silicated” is defined as “combined or impregnated with silicon or silica”; and “silicified” is defined as “convert[ed] into or impregnate[d] with silica”. Silicified microcrystalline cellulose, also called silicated microcrystalline cellulose, is a preferred auxiliary galenic agent. [0046]
  • In accordance with other embodiments of the present invention, the obtained free flowable powders comprise agglomerated particles may combined with conventional tableting additives prior to tableting, capsules filling, or further blending. Those additives may be soluble or insoluble inert pharmaceutical diluents, lubricants, agents for enteric, hydrophilic and hydrophobic coating, substances to achieve sustained and controlled release profile of the actives. In particular, the additives are suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, gelatin, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose and the like. Other additives include, e.g., antioxidants and preservatives, coloring, flavoring and diluting agents, emulsifying and suspending agents, such as acacia, agar, alginic acid, sodium alginate, bentonite, carbomer, carrageenan, carboxymethylcellulose, cellulose, cholesterol, gelatin, hydroxyethyl cellulose, hydroxppropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, oleyl alcohol, povidone, propylene glycol monostearate, sodium lauryl sulfate, sorbitan esters, stearyl alcohol, tragacanth, xanthan gum, and derivatives thereof, solvents, and miscellaneous ingredients such as microcrystalline cellulose, citric acid, dextrin, dextrose, fluid glucose, lactic acid, lactose, magnesium chloride, potassium metaphosphate, starch, and the like. Those components may either be co-sprayed or blended together with the product obtained according to the present invention. [0047]
  • The particle size of the additional substance employed is of less importance. Suitable particle sizes are within a range of 1 to 800 μm, preferably within the range of 1 to 500 μm, more preferably in the range of 100 to 300 μm. [0048]
  • Ratio of Active: Auxiliary
  • In accordance with another embodiment of the present invention, the orally applicable product form is provided, which comprises about 45-95%, preferably from 60 to 80%, active agent, in particular, a botanical extract and about 5 to 55%, preferably from 40 to 20%, of a galenic auxiliary agent added as dry powder during the spray drying process. [0049]
  • Structure of Agglomerated Particles
  • The structure of the spray dried powder particles is crucial for its physical characteristics. Thus, the physical properties of spray dried powders is related to the characteristics of the matrix of the shells (outer layer) and the size of the inner core. Using scanning electron microscopy (FIGS. [0050] 2-5) it can be shown that the particles obtained according to the present invent possess a shell of the added dry powder. Very impressive is comparison of FIGS. 4 and 5, where the difference of dry St. John's Wort extract particle (sole) and St. John's Wort particle produced according to the present invention (so called RediRun) is obvious.
  • EXAMPLES
  • In each of the following examples the products produced according to the invention were processed substantially as follows: A fluid extract is provided in a storage vessel. Also provided separately are dosing scales with the additional substance employed according to the invention in a dry form. The fluid extract or an aqueous solution of the active agent is sprayed into a drying chamber with the finely powdered additional substance at the top of the spray tower through high-pressure nozzles using a pump. Hot air is introduced into the spray tower from below (or top). The exhaust air leaves at the top end (or center) of the spray tower and is optionally conducted to a heat exchanger. The dried product is conducted onto a vibrating bed at the lower end of the spray tower and introduced into the further production process. Alternatively, the product may be fed into a cyclone. [0051]
  • Example 1
  • 146.5 kg of St. John's wort (SJW) extract having a dry content of 47.8% was spray-dried together with 30.00 kg of silicified/silicated microcrystalline cellulose at an air entry temperature of 210° C. and under a nozzle pressure of 40 bar to obtain 93.6 kg of dry product. [0052]
  • Comparative Example 1a
  • 5.0 kgs of commonly produced St. John's wort dry extract comprising of 65% native extract and about 35% excipients like Maltodextrin (30%) and silicon dioxide (5%) was added to 2,5 kgs of silicified/silicated microcrystalline cellulose and mixed in a pilot plant blender. The moisture uptake, the powder flowability and the compactability was compared with product of Example 1 in Table 1: [0053]
    TABLE 1
    Comparison of Properties of St. John's Wort Products
    Hardness of Hardness of
    Moisture Compact- the pressed the pressed Speed of
    Product Flowability Uptake ability tablets tablets Encapsulation
    St. John's Wort Very good Low Very good High High - No High - No
    of Example 1 stop stops necessary
    necessary
    St. John's Wort Good Fair Poor Fair Poor - Poor - Multiple
    of Comp. Multiple stop stops for
    Example 1 for cleaning cleaning
  • Speed of encapsulation: comparable trial was preformed at standard encapsulation machine (e.g., Bosch 330) to judge over the impact of flowability, dust formation, and moisture uptake on the velocity of capsule filling. [0054]
  • Example 2
  • 132.2 kgs of Panax ginseng (PG) extract having a dry content of 43.8% was spray-dried together with 25.0 kgs of silicified/silicated microcrystalline cellulose at an air entry temperature of 205° C. and under a nozzle pressure of 40 bar to obtain 83.6 kg of dry product. [0055]
  • Comparative Example 2a
  • 235.0 kgs of Panax ginseng (PG) extract having a dry content of 39.7% was spray-dried together with 23.3 kgs of physical mixture of microcrystalline cellulose and colloidal silicon dioxide (96% MCC and 4% SiO2, e.g., Aerosil) at an air entry temperature of 215° C. and under a nozzle pressure of 36 bar to obtain 83.6 kg of dry product. The moisture uptake, the powder flowability and the compactability was compared with product of Example 2. [0056]
  • Comparative Example 2b
  • 2.5 kgs of silicified/silicated microcrystalline cellulose was added to 4.5 kgs of commonly produced Panax ginseng dry extract comprising of 40% native extract and about 60% exicpients like Maltodextrin (55%) and silicon dioxide (5%) and mixed in a pilot plant blender. The moisture uptake, the powder flowability, compactability, and hardness of the tablets was compared with product of Example 2. [0057]
    TABLE 2
    Comparison of properties of Panax ginseng products
    Flow- Moisture Com- Hardness of the
    Product ability uptake pactability pressed tablets
    Panax of Example 2 very Low very good high
    good
    Panax of cp. very Low good high
    Example 2a good
    Panax of Comp. poor High poor fair
    Example 2b
  • Examples 3a-h
  • According to Example 1, similar products of the following botanical extracts and nutraceuticals or dietary supplements (DS) were manufactured. 15 to 245 kg fluid feed of below shown botanical extracts or dietary supplement solutions having a dry content of 32 to 53% were spray-dried together with 25 to 40% of dry silicified/silicated microcrystalline cellulose at an air entry temperature of 175-250° C. and under a nozzle pressure of about 40 bar to obtain dry product with yields of 85 to 95%. [0058]
    Botanical Extract/DS Characteristic Remarks
    Artichoke (Cynara scolymus) Free-flowing, fair hygroscopic Pure extract is extreme
    hygroscopic
    Echinacea (E. spp.) Low moisture uptake
    Eleuthococcus (E. senticosus) Free-flowing powder Pure extract tends to lump
    Gingko biloba Good to handle; fine powder
    Green tea (Camellia sinensis) Good compressible powder
    Garlic (Allium sativum) Powder with good flowability Raw material is sticky and
    hygroscopic.
    Horse chestnut (Aesculus Good compactable, fine
    hippocastanum) powder
    Glucosamine Fairly stabil powder product, Raw material is rather
    good compactable instabil espec. with
    moisture.
    Chrondroitin Free-flowing powder, good to Pure Chrondroitin takes
    handle moisture up.
  • Example 4
  • 5236.8 kg of St. John's wort extract having a dry content of 38% was spray-dried together with 104.6 kg of highly dispersed silica at an air entry temperature of 200° C. and under a nozzle pressure of 90 bar to obtain 2065.8 kg of dry product having a good flowability. [0059]
  • Example 5
  • 1819.9 kg of Giant or Late Goldenrod extract having a dry content of 30% was spray-dried together with 221.7 kg of maltodextrin and 23.4 kg of highly dispersed silica at an air entry temperature of 215° C. and under a nozzle pressure of 45 bar to obtain 733.6 kg of dry product. The product is a fine powder not sensitive to moisture. [0060]
  • Example 6
  • 1640.00 kg of valerian root extract having a dry content of 51.8% was spray-dried together with 332.00 kg of dry glucose and 48.6 kg of highly dispersed silica at an air entry temperature of 230° C. and under a nozzle pressure of 80 bar to obtain 1142.8 kg of dry free-flowing extract powder. [0061]
  • Example 7
  • 658.5 kg of nettle root extract having a dry content of 32% was spray-dried together with 52.7 kg of lactose at an air entry temperature of 220° C. and under a nozzle pressure of 50 bar to obtain 262.4 kg of dry free flowing product having good powder characteristics and is well to handle. [0062]
  • Example 8
  • According to Example 1, similar products comprising the dietary supplements Glucosamine and Chrondroitin with specialty auxiliary blend were manufactured. 47.6 kgs of Glucosamine sulfate and 38.1 kgs of Chrondroitin were dissolved in water to obtain the fluid feed. As dry powder feed a blend of dry silicified/silicated microcrystalline cellulose (11.9 kgs) and colloidal silicon dioxide (Aerosil 200; 2.4 kgs) were mixed. At an air entry temperature of 220° C. and under a nozzle pressure of about 40 bar the fluid and powder feed were co-spray-dried according to the example 1 to obtain dry product with yields of 93%. [0063]
  • Example 9
  • The same procedure as described in Example 8 using 45.2 kgs of Glucosamine sulfate and 36.2 kgs of Chrondroitin but a dry powder feed comprise 11,3 kgs of dry silicified/silicated microcrystalline cellulose, 2.3 kgs of colloidal silicon dioxide (Aerosil 200), 3.0 kgs of soy, polysaccharides, 1.5 kgs of Talkum, and 0.5 kgs of sodium stearylfumarate were used instead. The yield was 95.3 kgs of dry product. Both products of these examples (8 and 9) were fine, free flowable, and good compactable powder without tendency to lump. [0064]

Claims (36)

We claim:
1. A process for preparing dry extracts from a fluid extract and at least one additional substance by a spray-drying process, wherein said at least one additional substance is added to the spray-drying process in a dry form during the spray-drying process.
2. The process according to claim 1, wherein said fluid extract is the extract of a medicinal plant.
3. The process according to claim 1 or 2, wherein said at least one additional substance is a galenic auxiliary agent.
4. The process according to claim 3, wherein in that said auxiliary agent is selected from the group consisting of lactose, maltodextrin, dextrin, dry glucose, starch, microcrystalline cellulose, silicated/silicified microcrystalline cellulose, Povidone®, polyethylene glycol, calcium phosphate, magnesium stearate, precipitated silica acid, precipitated silica, highly dispersed silica, sorbitol, mannitol, ir mixtures thereof.
5. The process according to claim 1, wherein the particle size of said at least one additional substance is within a range of from 1 to 500 μm.
6. A dry extract obtained by a process according to claim 1.
7. A medicament containing a dry extract according to claim 6.
8. The medicament of claim 7 in the form of a tablet.
9. A process for preparing agglomerated particles containing an active agent, comprising the steps of:
(a) providing droplets of a fluid, said fluid containing said active agent;
(b) mixing said droplets with dispersed particles of a solid phase component; and
(c) drying said mixture.
10. A process for preparing a dry composition containing an active agent, said process comprising the steps of:
(a) atomizing a fluid which contains said active agent;
(b) dispersing a solid component in the presence of said atomized fluid; and
(c) contacting said fluid and said solid component with a heated gas.
11. A solid dosage form comprising an active agent and an auxiliary agent, the dosage form formed by:
(a) combining said active agent in fluid form with a solid phase component to form agglomerated particles; and
(b) incorporating the agglomerated particles into a solid dosage form.
12. The process of claim 9, wherein said fluid comprises St. John's Wort, and wherein said solid phase comprises silicified/silicated microcrystalline cellulose.
13. The process of claim 9, wherein said fluid comprises panax ginseng, and wherein said solid phase comprises silicified/silicated microcrystalline cellulose.
14. The process of claim 9, wherein said fluid comprises artichoke (Cynara scolymus), and wherein said solid phase comprises silicified/silicated microcrystalline cellulose.
15. The process of claim 9, wherein said fluid comprises echinacea (E. spp.), and wherein said solid phase comprises silicified/silicated microcrystalline cellulose.
16. The process of claim 9, wherein said fluid comprises eleuthococcus (E. senticosus), and wherein said solid phase comprises silicified/silicated microcrystalline cellulose.
17. The process of claim 9, wherein said fluid comprises ginkgo biloba, and wherein said solid phase comprises silicified/silicated microcrystalline cellulose.
18. The process of claim 9, wherein said fluid comprises green tea (Camellia sinensis), and wherein said solid phase comprises silicified/silicated microcrystalline cellulose.
19. The process of claim 9, wherein said fluid comprises garlic (Allium sativum), and wherein said solid phase comprises silicified/silicated microcrystalline cellulose.
20. The process of claim 9, wherein said fluid comprises horse chestnut (Aesculus hippocastanum), and wherein said solid phase comprises silicified/silicated microcrystalline cellulose.
21. The process of claim 9, wherein said fluid comprises glucosamine, and wherein said solid phase comprises silicified/silicated microcrystalline cellulose.
22. The process of claim 9, wherein said fluid comprises chondroitin, and wherein said solid phase comprises silicified/silicated microcrystalline cellulose.
23. The process of claim 9, wherein said fluid comprises St. John's Wort, and wherein said solid phase comprises silica.
24. The process of claim 9, wherein said fluid comprises goldenrod, and wherein said solid phase comprises silica and maltodextrin.
25. The process of claim 9, wherein said fluid comprises valerian root, and wherein said solid phase comprises silica and dry glucose.
26. The process of claim 9, wherein said fluid comprises nettle root, and wherein said solid phase comprises lactose.
27. A process for manufacturing agglomerated particles containing an active agent, comprising combining a fluid containing said active agent with a particles of a solid phase component in a dryer to form agglomerated particles.
28. A process for preparing a dry composition containing an active agent, comprising co-spraying a fluid, said fluid containing an active agent, and particles of a solid phase component, to form agglomerated particles.
29. The process of claim 9, further comprising the step of compressing said mixture to form a tablet.
30. The agglomerated particles obtained by the process according to claim 9.
31. The dry composition obtained by the process according to claim 10.
32. The agglomerated particles obtained by the process according to claim 27.
33. The dry composition obtained by the process according to claim 28.
34. The solid dosage form of claim 11, wherein said solid dosage form is selected from the group consisting of tablets, capsules, and entire coated tablets.
35. The agglomerated particles of claim 30 in a solid dosage form, said solid dosage form comprising one or more of tablets, capsules and entire coated tablets.
36. The agglomerated particles of claim 32 in a solid dosage form, said solid dosage form comprising one or more of tablets, capsules and entire coated tablets.
US10/290,121 2001-11-07 2002-11-07 Process for preparing dry extracts Abandoned US20030104076A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/290,121 US20030104076A1 (en) 2001-11-07 2002-11-07 Process for preparing dry extracts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/986,116 US6753017B2 (en) 2001-11-07 2001-11-07 Process for preparing dry extracts
US10/290,121 US20030104076A1 (en) 2001-11-07 2002-11-07 Process for preparing dry extracts

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/986,116 Continuation-In-Part US6753017B2 (en) 2001-11-07 2001-11-07 Process for preparing dry extracts

Publications (1)

Publication Number Publication Date
US20030104076A1 true US20030104076A1 (en) 2003-06-05

Family

ID=25532095

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/986,116 Expired - Fee Related US6753017B2 (en) 2001-11-07 2001-11-07 Process for preparing dry extracts
US10/290,121 Abandoned US20030104076A1 (en) 2001-11-07 2002-11-07 Process for preparing dry extracts

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/986,116 Expired - Fee Related US6753017B2 (en) 2001-11-07 2001-11-07 Process for preparing dry extracts

Country Status (7)

Country Link
US (2) US6753017B2 (en)
EP (1) EP1443909A1 (en)
JP (1) JP2005515174A (en)
CN (1) CN1326517C (en)
PL (1) PL368307A1 (en)
RU (1) RU2004117089A (en)
WO (1) WO2003039515A1 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182259A1 (en) * 1996-06-10 2002-12-05 Staniforth John N. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
US20040156926A1 (en) * 2003-02-10 2004-08-12 Triarco Industries, Inc. Method of inhibiting aromatase with specific dietary supplements
US20040204382A1 (en) * 2003-04-08 2004-10-14 Janeel Henderson Energy generating composition
WO2005041869A2 (en) * 2003-10-24 2005-05-12 Josef Rettenmaier & Soehne Gmbh & Co., Kg Process for co-spray drying agents with dry silicified mcc
US20050276870A1 (en) * 2004-06-10 2005-12-15 D & E Pharmaceuticals, Inc. Food supplement formulation
FR2876586A1 (en) * 2004-10-20 2006-04-21 Persee Medica COMPOSITION FOR PREVENTING OR TREATING STRESS, INCLUDING CHRONIC AND PERMANENT STRESS BURNS
US20060115556A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplement drink containing xanthone extracts
US20060115555A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
US20060228487A1 (en) * 2005-04-11 2006-10-12 J. Rettenmaier & Söehne GmbH + Co. KG Methods of combining active agents with augmented microcrystalline cellulose
US20070184163A1 (en) * 2006-02-07 2007-08-09 International Flavors, & Fragrances Inc. Non-hygroscopic flavor particles
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
US20080095719A1 (en) * 2004-06-18 2008-04-24 Symrise Gmbh & Co. Kg Blackberry Extract
WO2009009530A1 (en) * 2007-07-09 2009-01-15 Selvamedica, Llc Maytenus abenfolia extract and methods of extracting and using such extract
US20090074942A1 (en) * 2005-05-17 2009-03-19 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
US20090117209A1 (en) * 2007-11-02 2009-05-07 Hutchison Medipharma Enterprises Limited Andrographis paniculata extract
US20090130075A1 (en) * 2003-04-08 2009-05-21 Janeel Henderson Energy generating composition
WO2010050684A2 (en) * 2008-10-28 2010-05-06 Amorepacific Corporation Perfume composition for expressing the fragrance of silk tree flower
US7833777B2 (en) 2005-08-22 2010-11-16 Nature Technologies International Llc Stabilized actively aerated compost tea
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
US20110117263A1 (en) * 2009-11-18 2011-05-19 Young-Sam Jang Health tea and method for preparing the same
US20110165275A1 (en) * 2008-09-24 2011-07-07 Maria Grazia Canaline Preparation for the treatment of the erectile disorder
USRE42718E1 (en) 2004-04-28 2011-09-20 Hutchison Medipharma Enterprises Limited Crude extracts from andrographis paniculata
US20130153157A1 (en) * 2010-09-03 2013-06-20 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US20130165371A1 (en) * 2010-09-03 2013-06-27 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US20130287868A1 (en) * 2007-02-15 2013-10-31 Ache Laboratorios Farmauceticos S/A Pharmaceutical composition on the basis of Stachytarpheta sp., a process for obtaining the same and its use for treating vitiligo
US20130344180A1 (en) * 2012-06-26 2013-12-26 Yl Holdings, Inc. Weight loss and satiation composition
RU2532343C2 (en) * 2009-09-02 2014-11-10 ЭКСЕСС БИЗНЕСС ГРУП ИНТЕРНЭШНЛ ЭлЭлСи Skin regeneration composition and method
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
US20150351408A1 (en) * 2014-06-04 2015-12-10 Patagonia Biotecnología S.A. Process to elaborate a biostimulant based on seaweeds
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
US9724664B2 (en) 2009-03-27 2017-08-08 Bend Research, Inc. Spray-drying process
US11364203B2 (en) 2014-10-31 2022-06-21 Bend Reserch, Inc. Process for forming active domains dispersed in a matrix

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
EP1575487B1 (en) 2002-05-14 2019-08-14 DuPont Nutrition USA, Inc. Coattrited microcrystalline cellulose hydrocolloid compositions and method for manufacture
JP4703972B2 (en) * 2004-04-01 2011-06-15 株式会社日清製粉グループ本社 Mixing equipment
US7879382B2 (en) * 2005-09-30 2011-02-01 Fmc Corporation Stabilizers and compositions and products comprising same
DE602007011792D1 (en) 2006-10-27 2011-02-17 Fmc Corp COMMONLY PREPARED MICROCRYSTALLINE CELLULOSE AND SUGAR ALCOHOL AS AN AUXILIARY FOR TABLET FORMULATIONS
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
JP4914480B2 (en) * 2009-11-18 2012-04-11 ヤン‐サム チャン Natural health tea and method for producing the same
BRPI1000802B8 (en) * 2010-03-30 2021-09-08 Apis Flora Indl Coml Ltda process for obtaining langsdorffii copaiferous matrix microparticles (aerial parts) and langsdorffii copaiferous matrix microparticles
CN103857739B (en) 2011-10-05 2017-04-19 Fmc有限公司 Stabilizer composition of co-attrited microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
EP2764046B1 (en) 2011-10-05 2021-04-21 DuPont Nutrition USA, Inc. Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
EP2787837B1 (en) 2011-12-09 2017-03-15 FMC Corporation Co-attrited stabilizer composition
BR112014025518B1 (en) 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Aggregate particles of umeclidinium, vilanterol and fluticasone, powder composition, inhaler, process for preparing aggregate particles, and, use of magnesium stearate in aggregate particles
WO2016098881A1 (en) * 2014-12-19 2016-06-23 協和発酵バイオ株式会社 Tablet containing high amounts glucosamine and chondroitin sulfate, and method for producing same
JP6716940B2 (en) * 2015-02-26 2020-07-01 大正製薬株式会社 Extract powder
FR3082122B1 (en) * 2018-06-11 2021-01-01 Basf Beauty Care Solutions France Sas USE OF A BIXA ORELLANA EXTRACT

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2627463A (en) * 1949-07-09 1953-02-03 Western Condensing Co Process for the manufacture of stabilized milk products
US2756177A (en) * 1953-03-09 1956-07-24 Hoffmann La Roche Process for making fat-soluble vitamin active powder
US3615723A (en) * 1970-04-15 1971-10-26 Pillsbury Co Spray-drying apparatus
US4317743A (en) * 1979-12-05 1982-03-02 Wallace Business Forms, Inc. Process for making microcapsules and resulting product
US4395491A (en) * 1980-02-15 1983-07-26 Hoechst Aktiengesellschaft Method for isolating solid matter from a salinomycin culture broth
US4519961A (en) * 1981-09-05 1985-05-28 Basf Aktiengesellschaft Production of dry powders of substances which are sensitive to oxidation
US4533674A (en) * 1983-10-24 1985-08-06 Basf Wyandotte Corporation Process for preparing a sugar and starch free spray-dried vitamin C powder containing 90 percent ascorbic acid
US4892889A (en) * 1986-11-18 1990-01-09 Basf Corporation Process for making a spray-dried, directly-compressible vitamin powder comprising unhydrolyzed gelatin
US4938998A (en) * 1985-08-24 1990-07-03 Juergen Stock Process for treating the surface of a plastic article
US5466452A (en) * 1991-02-28 1995-11-14 Phytopharm Ltd. Pharmaceutical compositions for the treatment of skin disorders
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5709880A (en) * 1995-07-10 1998-01-20 Buckman Laboratories International, Inc. Method of making tabletized ionene polymers
US5714168A (en) * 1996-12-11 1998-02-03 Basf Corporation Method for increasing flowability of spray dried vitamin powders having low vitamin concentrations
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US5741478A (en) * 1994-11-19 1998-04-21 Andaris Limited Preparation of hollow microcapsules by spray-drying an aqueous solution of a wall-forming material and a water-miscible solvent
US5741524A (en) * 1995-01-09 1998-04-21 Edward Mendell Co., Inc. Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility
US5776240A (en) * 1995-02-04 1998-07-07 Degussa Aktiengesellschaft Granules based on pyrogenically prepared silicon dioxide, methods for their preparation and use thereof
US5798101A (en) * 1997-01-22 1998-08-25 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US6030645A (en) * 1997-02-28 2000-02-29 Roche Vitamins Inc. Free-flowing dry particles
US6054144A (en) * 1998-02-19 2000-04-25 Mcneil-Ppc, Inc. Method for producing water dispersible sterol formulations
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US6117451A (en) * 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
US6153220A (en) * 1997-10-03 2000-11-28 Elan Corporation, Plc Taste-masked formulations
US6165503A (en) * 1997-07-07 2000-12-26 Fmc Biopolymer A.S. High strength capsules, process of preparing and using the same
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
US6383526B1 (en) * 1999-07-21 2002-05-07 Ancile Pharmaceuticals, Inc. Process for the extraction of valerian root
US6391337B2 (en) * 1995-11-15 2002-05-21 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US6395303B1 (en) * 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
US6447815B1 (en) * 2000-12-19 2002-09-10 Access Business Group International Llc Heated alcohol extraction of herbs
US6495142B2 (en) * 2000-09-13 2002-12-17 Kazuo Sakai Methods for treatment of impulse control disorders
US20030073316A1 (en) * 1998-12-07 2003-04-17 Taiwan Semiconductor Manufacturing Company Novel post etching treatment process for high density oxide etcher
US6627210B2 (en) * 2000-07-14 2003-09-30 Allergan, Inc. Compositions containing α-2-adrenergic agonist components
US6872336B2 (en) * 2001-09-05 2005-03-29 Shin-Etsu Chemical Co., Ltd. Process for producing a pharmaceutical solid preparation containing a poorly soluble drug
US7179488B2 (en) * 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB417552A (en) 1933-12-18 1934-10-08 Metallgesellschaft Ag Process for the production of stable mixtures containing vegetable lecithin with or without soya oil
GB1098065A (en) 1964-10-22 1968-01-03 Lafon Victor Improvements in or relating to extracts of marrubium
FR2651127B1 (en) * 1989-08-30 1994-06-03 Chevance Leon NOVEL USE OF SUBSTANCES AS ANTI-COMPONENTS AND MEDICINES CONTAINING SUCH A SUBSTANCE.
JPH06192113A (en) * 1992-09-25 1994-07-12 Powrex:Kk Method for granulating galenicals and solid pharmaceutical preparation
FI109088B (en) 1997-09-19 2002-05-31 Leiras Oy Tablet and process for its preparation
CN1124148C (en) 2001-01-21 2003-10-15 程志清 Traditional Chinese medicine for curing viral myocarditis and its preparing process

Patent Citations (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2627463A (en) * 1949-07-09 1953-02-03 Western Condensing Co Process for the manufacture of stabilized milk products
US2756177A (en) * 1953-03-09 1956-07-24 Hoffmann La Roche Process for making fat-soluble vitamin active powder
US3615723A (en) * 1970-04-15 1971-10-26 Pillsbury Co Spray-drying apparatus
US4317743A (en) * 1979-12-05 1982-03-02 Wallace Business Forms, Inc. Process for making microcapsules and resulting product
US4395491A (en) * 1980-02-15 1983-07-26 Hoechst Aktiengesellschaft Method for isolating solid matter from a salinomycin culture broth
US4519961A (en) * 1981-09-05 1985-05-28 Basf Aktiengesellschaft Production of dry powders of substances which are sensitive to oxidation
US4533674A (en) * 1983-10-24 1985-08-06 Basf Wyandotte Corporation Process for preparing a sugar and starch free spray-dried vitamin C powder containing 90 percent ascorbic acid
US4938998A (en) * 1985-08-24 1990-07-03 Juergen Stock Process for treating the surface of a plastic article
US4892889A (en) * 1986-11-18 1990-01-09 Basf Corporation Process for making a spray-dried, directly-compressible vitamin powder comprising unhydrolyzed gelatin
US5466452A (en) * 1991-02-28 1995-11-14 Phytopharm Ltd. Pharmaceutical compositions for the treatment of skin disorders
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US5741478A (en) * 1994-11-19 1998-04-21 Andaris Limited Preparation of hollow microcapsules by spray-drying an aqueous solution of a wall-forming material and a water-miscible solvent
US6521261B2 (en) * 1995-01-09 2003-02-18 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5725883A (en) * 1995-01-09 1998-03-10 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5725884A (en) * 1995-01-09 1998-03-10 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US6358533B2 (en) * 1995-01-09 2002-03-19 Edward Mendell, Co., Inc. Pharmaceutical excipient having improved compressibility
US6103219A (en) * 1995-01-09 2000-08-15 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5741524A (en) * 1995-01-09 1998-04-21 Edward Mendell Co., Inc. Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility
US6217909B1 (en) * 1995-01-09 2001-04-17 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5858412A (en) * 1995-01-09 1999-01-12 Edward Mendell Co., Inc. Sustained release formulations utilizing pharmaceutical excipient having improved compressibility with modified microcrystalline
US5866166A (en) * 1995-01-09 1999-02-02 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5776240A (en) * 1995-02-04 1998-07-07 Degussa Aktiengesellschaft Granules based on pyrogenically prepared silicon dioxide, methods for their preparation and use thereof
US5709880A (en) * 1995-07-10 1998-01-20 Buckman Laboratories International, Inc. Method of making tabletized ionene polymers
US6217907B1 (en) * 1995-11-15 2001-04-17 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US5965166A (en) * 1995-11-15 1999-10-12 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US6391337B2 (en) * 1995-11-15 2002-05-21 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US6395303B1 (en) * 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
US5714168A (en) * 1996-12-11 1998-02-03 Basf Corporation Method for increasing flowability of spray dried vitamin powders having low vitamin concentrations
US5798101A (en) * 1997-01-22 1998-08-25 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
US6030645A (en) * 1997-02-28 2000-02-29 Roche Vitamins Inc. Free-flowing dry particles
US6165503A (en) * 1997-07-07 2000-12-26 Fmc Biopolymer A.S. High strength capsules, process of preparing and using the same
US6153220A (en) * 1997-10-03 2000-11-28 Elan Corporation, Plc Taste-masked formulations
US6054144A (en) * 1998-02-19 2000-04-25 Mcneil-Ppc, Inc. Method for producing water dispersible sterol formulations
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
US6117451A (en) * 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
US20030073316A1 (en) * 1998-12-07 2003-04-17 Taiwan Semiconductor Manufacturing Company Novel post etching treatment process for high density oxide etcher
US6383526B1 (en) * 1999-07-21 2002-05-07 Ancile Pharmaceuticals, Inc. Process for the extraction of valerian root
US6627210B2 (en) * 2000-07-14 2003-09-30 Allergan, Inc. Compositions containing α-2-adrenergic agonist components
US6495142B2 (en) * 2000-09-13 2002-12-17 Kazuo Sakai Methods for treatment of impulse control disorders
US6447815B1 (en) * 2000-12-19 2002-09-10 Access Business Group International Llc Heated alcohol extraction of herbs
US6872336B2 (en) * 2001-09-05 2005-03-29 Shin-Etsu Chemical Co., Ltd. Process for producing a pharmaceutical solid preparation containing a poorly soluble drug
US7179488B2 (en) * 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182259A1 (en) * 1996-06-10 2002-12-05 Staniforth John N. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
US6866867B2 (en) 1996-06-10 2005-03-15 J. Rettenmaier & Soehne Gmbh + Co. Kg Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
US20040156926A1 (en) * 2003-02-10 2004-08-12 Triarco Industries, Inc. Method of inhibiting aromatase with specific dietary supplements
US7731992B2 (en) * 2003-02-10 2010-06-08 Triarco Industries, Inc. Method of inhibiting aromatase with specific dietary supplements
US20040204382A1 (en) * 2003-04-08 2004-10-14 Janeel Henderson Energy generating composition
US7968125B2 (en) 2003-04-08 2011-06-28 Janeel Henderson Energy generating composition
US7455857B2 (en) * 2003-04-08 2008-11-25 Janeel Henderson Energy generating composition
US20090130075A1 (en) * 2003-04-08 2009-05-21 Janeel Henderson Energy generating composition
WO2005041869A2 (en) * 2003-10-24 2005-05-12 Josef Rettenmaier & Soehne Gmbh & Co., Kg Process for co-spray drying agents with dry silicified mcc
WO2005041869A3 (en) * 2003-10-24 2005-09-22 Josef Rettenmaier & Soehne Gmb Process for co-spray drying agents with dry silicified mcc
USRE42718E1 (en) 2004-04-28 2011-09-20 Hutchison Medipharma Enterprises Limited Crude extracts from andrographis paniculata
USRE43423E1 (en) 2004-04-28 2012-05-29 Hutchison Medipharma Enterprises Limited Crude extracts from Andrographis paniculata
US7390513B2 (en) * 2004-06-10 2008-06-24 D & E Pharmaceuticals Food supplement formulation
US20050276870A1 (en) * 2004-06-10 2005-12-15 D & E Pharmaceuticals, Inc. Food supplement formulation
US9987217B2 (en) * 2004-06-18 2018-06-05 Symrise Ag Blackberry extract
US20080095719A1 (en) * 2004-06-18 2008-04-24 Symrise Gmbh & Co. Kg Blackberry Extract
WO2006042928A1 (en) * 2004-10-20 2006-04-27 Persee Medica Composition for preventing or treating stress, especially chronic and permanent bursts of stress
FR2876586A1 (en) * 2004-10-20 2006-04-21 Persee Medica COMPOSITION FOR PREVENTING OR TREATING STRESS, INCLUDING CHRONIC AND PERMANENT STRESS BURNS
US20060115555A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
US20060115556A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplement drink containing xanthone extracts
US20060228487A1 (en) * 2005-04-11 2006-10-12 J. Rettenmaier & Söehne GmbH + Co. KG Methods of combining active agents with augmented microcrystalline cellulose
US20090074942A1 (en) * 2005-05-17 2009-03-19 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
US8535750B2 (en) 2005-05-17 2013-09-17 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
US7833777B2 (en) 2005-08-22 2010-11-16 Nature Technologies International Llc Stabilized actively aerated compost tea
US20070184163A1 (en) * 2006-02-07 2007-08-09 International Flavors, & Fragrances Inc. Non-hygroscopic flavor particles
US20110142944A1 (en) * 2006-02-28 2011-06-16 Hutchison Medipharma Enterprises Limited, Offshore Group Chambers Andrographis extract formulations
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
US20130287868A1 (en) * 2007-02-15 2013-10-31 Ache Laboratorios Farmauceticos S/A Pharmaceutical composition on the basis of Stachytarpheta sp., a process for obtaining the same and its use for treating vitiligo
WO2009009530A1 (en) * 2007-07-09 2009-01-15 Selvamedica, Llc Maytenus abenfolia extract and methods of extracting and using such extract
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
US8557308B2 (en) * 2007-11-02 2013-10-15 Nutrition Science Partners Limited Andrographis paniculata extract
US20090117210A1 (en) * 2007-11-02 2009-05-07 Hutchison Medipharma Enterprises Limited Andrographis paniculata extract
US20090117209A1 (en) * 2007-11-02 2009-05-07 Hutchison Medipharma Enterprises Limited Andrographis paniculata extract
US20130023493A1 (en) * 2007-11-02 2013-01-24 Hutchison Medipharma Enterprises Limited Andrographis paniculata extract
US8557302B2 (en) * 2007-11-02 2013-10-15 Nutrition Science Partners Limited Andrographis paniculata extract
US20110165275A1 (en) * 2008-09-24 2011-07-07 Maria Grazia Canaline Preparation for the treatment of the erectile disorder
WO2010050684A2 (en) * 2008-10-28 2010-05-06 Amorepacific Corporation Perfume composition for expressing the fragrance of silk tree flower
WO2010050684A3 (en) * 2008-10-28 2010-08-19 Amorepacific Corporation Perfume composition for expressing the fragrance of silk tree flower
US9724664B2 (en) 2009-03-27 2017-08-08 Bend Research, Inc. Spray-drying process
US10300443B2 (en) 2009-03-27 2019-05-28 Bend Research, Inc. Spray-drying process
US10675602B2 (en) 2009-03-27 2020-06-09 Bend Research, Inc. Spray-drying process
RU2532343C2 (en) * 2009-09-02 2014-11-10 ЭКСЕСС БИЗНЕСС ГРУП ИНТЕРНЭШНЛ ЭлЭлСи Skin regeneration composition and method
US20110117263A1 (en) * 2009-11-18 2011-05-19 Young-Sam Jang Health tea and method for preparing the same
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
US9084944B2 (en) * 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9084976B2 (en) * 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9205345B2 (en) 2010-09-03 2015-12-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US20130165371A1 (en) * 2010-09-03 2013-06-27 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9358478B2 (en) 2010-09-03 2016-06-07 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US20130153157A1 (en) * 2010-09-03 2013-06-20 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
US20130344180A1 (en) * 2012-06-26 2013-12-26 Yl Holdings, Inc. Weight loss and satiation composition
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders
US9854810B2 (en) * 2014-06-04 2018-01-02 Patagonia Biotecnología S.A. Process to elaborate a biostimulant based on seaweeds
US20150351408A1 (en) * 2014-06-04 2015-12-10 Patagonia Biotecnología S.A. Process to elaborate a biostimulant based on seaweeds
US11364203B2 (en) 2014-10-31 2022-06-21 Bend Reserch, Inc. Process for forming active domains dispersed in a matrix

Also Published As

Publication number Publication date
WO2003039515A1 (en) 2003-05-15
PL368307A1 (en) 2005-03-21
CN1582144A (en) 2005-02-16
US6753017B2 (en) 2004-06-22
US20030086982A1 (en) 2003-05-08
EP1443909A1 (en) 2004-08-11
CN1326517C (en) 2007-07-18
JP2005515174A (en) 2005-05-26
RU2004117089A (en) 2005-04-10

Similar Documents

Publication Publication Date Title
US20030104076A1 (en) Process for preparing dry extracts
US10729662B2 (en) Product comprising a plant for medicinal, cosmetic, coloring or dermatologic use
US20200368303A1 (en) Composition comprising a mixture of molecules extracted from chrysanthellum indicum, cynara scolymus and lycium barbarum and use to act on carbohydrate and/or fat metabolism
US20200121624A1 (en) Magnesium compositions and methods of use
JP5979931B2 (en) Pharmaceutical composition
EP3982924B1 (en) Plant extract mixture for use in the prevention and/or treatment of chronic inflammatory bowel diseases
RU2155062C1 (en) Method of preparing drug with enhanced activity and drug
EP1281403A1 (en) Dietetic and/or pharmaceutical compositions containing a plant extract and probiotic microorganisms
DE202019102955U1 (en) Water-soluble beverage powder
CN107519293A (en) A kind of benzydamine micropill and preparation method thereof
Bowen et al. Adverse Effects of Herbal Drugs 2
US20210212929A1 (en) Oral formulations for mitigating acute cannabis intoxication
EP3821878A1 (en) Water-soluble tablets, velotransfer technology
WO2009093736A1 (en) Tablet comprising kanpo herbal medicine and pantethine component
HRP970392A2 (en) Medicaments containing plant extracts
JP5224834B2 (en) Tablets containing processed plant products and panthetins
JP7158831B2 (en) Tablet containing goshitsu processed material
CN1537599A (en) Danshi Tongli granule for discharging biliary calculus, and its prepn. method
CN115737570A (en) Method for reducing hygroscopicity of spray-dried particles of traditional Chinese medicine extract
CN1552372A (en) Pills against gynecologic inflammation and their preparation
CN1548083A (en) Cholelithiasis treating bolus and its prepn
CN1548094A (en) Head-wind syndrome treating gastrodia tuber bolus and its prepn

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION